Software modelisation for a better understanding of pharmacokinetic/ pharmacodynamic relationships: Application to azithromycin in the treatment of streptococcal tonsillitis and in acute exacerbation of chronic bronchitis;Une modélisation informatique pour une meilleure compréhension de la relation PK/PD: Application à l'azithromycine dans le traitement de l'angine aiguë streptococcique et des exacerbations aiguës de la bronchite chronique

Therapie

Volumn 59, Issue 1, 2004, Pages 155-162

  Le Normand, Yves ^a   Drugeon, Henri ^b   Abbas, Sarah ^c   Palestro, Brigitte ^c  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c PFIZER INC   (United States)

Author keywords

Azithromycin; Pharmacodynamics; Pharmacokinetics; Simulation

Indexed keywords

AZITHROMYCIN; MACROLIDE;

AREA UNDER THE CURVE; CHRONIC BRONCHITIS; COMPUTER PROGRAM; COMPUTER SIMULATION; CONFERENCE PAPER; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TISSUE LEVEL; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG PARENCHYMA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARAMETER; PHARMACODYNAMICS; PLASMA; PREDICTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; TONSILLITIS;

EID: 2942639531     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2004030     Document Type: Conference Paper

References (36)

1. Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 2002; 19: 355-8
2. Van Bambeke F, Tulkens PM. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2001; 18 Suppl. 1: S17-23
3. Amsden GW, Ballow CH, Forrest A. Comparison of the plasma, urine and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects. Clin Drug Invest 1997; 13: 152-61
4. Cooper MA, Nye K, Andrews JM, et al. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. J Antimicrob Chemother 1990; 26: 533-8
5. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 Suppl. A: 73-82
6. Fourtillan JB. Propriétés pharmacocinétiques des nouveaux macrolides. A propos de l'azithromycine. Méd Mal Infect 1995; 25: 1142-52
7. Mazzei T, Surrenti C, Novelli A, et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J Antimicrob Chemother 1993; 31 Suppl. E: 57-63
8. Ripa S, Ferrante L, Prenna M. A linear model for the pharmacokinetics of azithromycin in healthy volunteers. Chemotherapy 1996; 42: 402-9
9. Wildfeuer A, Laufen H, Leitold M, et al. Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine. J Antimicrob Chemother 1993; 31 Suppl. E: 51-6
10. Wildfeuer A, Laufen H, Zimmermann T. Distribution of orally administered azithromycin in various blood compartments. Int J Clin Pharmacol Therap 1994; 32: 356-60
11. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc., 1982
12. Rowland M, Tozer TN. Clinical pharmacokinetics. 2nd ed. Philadelphia (PA): Lea and Febiger, 1989
13. Le Normand Y. Simulation de la pharmacocinétique de l'azithromycine (Zithromax®). Contribution au dossier d'autorisation de mise sur le marché (AMM), 1999
14. Le Normand Y, Drugeon HB, Potel G, et al. Teaching individualized antibiotic dosage regimens by means of two computer-assisted programs. Int J Biomed Comput 1994; 36: 117-9
15. Le Normand Y, Ortega A, Mazéas M. Tobra-Didact: a computer program for teaching individual adaptation of tobramycin therapy. Eur J Pharmacol 1990; 183 Suppl. 3: 923-4
16. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991; 91 Suppl. 3A: 5S-11S
17. Singlas E. Etude de la diffusion amygdalienne de l'azithromycine administrée par voie orale pendant 3 jours. Dossier d'autorisation de mise sur le marché (AMM): Etude AZM-F-92001
18. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992; 36: 1176-80
19. Bergogne-Bérézin E. Pharmacocinétique des antibiotiques dans les voies respiratoires inférieures. Limites de l'apport de cette information. Méd Mal Infect 1992; 22: 103-13
20. Fourtillan JB. Cinétique de distribution des antibiotiques dans la sphère bronchopulmonaire. Rev Pneumol Clin 1996; 52 Suppl. 2: S43-6
21. Neu HC. Activity of macrolides against common pathogens in vitro. In: Brysker AJ, Butzler JP, Neu HC, et al., editors. Macrolides: chemistry, pharmacology and clinical uses. Paris: Arnette Blackwell, 1993: 197-203
22. Hacker J, Hof H. Biology and experimental chemotherapy of Legionella infections. In: Brysker AJ, Butzler JP, Neu HC, et al., editors. Macrolides: chemistry, pharmacology and clinical uses. Paris: Arnette Blackwell, 1993: 229-34
23. Orfila J. Antimycoplasmal activity of macrolides. In: Brysker AJ, Butzler JP, Neu HC, et al., editors. Macrolides: chemistry, pharmacology and clinical uses. Paris: Arnette Blackwell, 1993: 253-60
24. Orfila J. Chlamydial infections. In: Brysker AJ, Butzler JP, Neu HC, et al., editors. Macrolides: chemistry, pharmacology and clinical uses. Paris: Arnette Blackwell, 1993: 241-52
25. Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chemother 1993; 31 Suppl. E: 39-50
26. Fourtillan JB. Pharmacokinetic handling of azithromycin after administration of oral and intravenous single doses, and multiple dosing in 12 healthy volunteers. Dossier d'autorisation de mise sur le marché (AMM): Etude AZM-F-93004
27. Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 1997; 16: 438-43
28. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 Suppl. 3: 38-44
29. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12
30. Craig WA. Does the dose matter? Clin Infect Dis 2001; 33: S223-37
31. Rodvold KA, Gotfried MH, Danziger LH, et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997; 41: 1399-402
32. Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996; 40: 2375-9
33. Baldwin DR, Wise R, Andrews JM, et al. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990; 3: 886-90
34. Olsen KM, San Pedro G, Gann LP, et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996; 40: 2582-5
35. Conte Jr JE, Golden J, Duncan S, et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 1996; 40: 1617-22
36. Nix DE. Intrapulmonary concentrations of antimicrobial agents. Infect Dis Clin North Am 1998; 12: 631-46